Lyell Immunopharma, Inc.
LYEL
$10.76
-$0.21-1.91%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 14.29% | -36.36% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 14.29% | -36.36% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 14.29% | -36.36% | |||
| SG&A Expenses | -30.33% | -3.28% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 5.11% | 1.88% | |||
| Total Operating Expenses | -22.78% | -9.18% | |||
| Operating Income | 22.79% | 9.18% | |||
| Income Before Tax | 18.22% | 72.81% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 18.22% | 72.81% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 18.22% | 72.81% | |||
| EBIT | 22.79% | 9.18% | |||
| EBITDA | 23.70% | 7.20% | |||
| EPS Basic | 18.43% | 74.20% | |||
| Normalized Basic EPS | 23.86% | 14.25% | |||
| EPS Diluted | 18.43% | 74.20% | |||
| Normalized Diluted EPS | 23.86% | 14.25% | |||
| Average Basic Shares Outstanding | 0.26% | 5.41% | |||
| Average Diluted Shares Outstanding | 0.26% | 5.41% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||